Kurtis J Swartz

Dr. Kurtis J Swartz

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2023 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
MBMoise Bonheur
Moise Bonheur
KSKurtis J Swartz
Kurtis J Swartz
MMMelissa G. Metcalf
Melissa G. Metcalf
XWXinke Wen
Xinke Wen
AZAnna Zhukovskaya
Anna Zhukovskaya
DHDaisuke Hattori
Daisuke Hattori

Verified
Journal Article
Open access
PDF file
HAHussein Alawieh
Hussein Alawieh
KSKurtis J Swartz
Kurtis J Swartz
SRStephanie K Rigot
Stephanie K Rigot
JCJonathan D. Charlesworth
Jonathan D. Charlesworth
Background: Restless legs syndrome (RLS) is a prevalent neurological sleep disorder that often impairs sleep maintenance. This single-arm, open-label study evaluated the efficacy, safety, and tolerability of extended-duration tonic motor activation (XD-TOMAC) in adults with RLS who experience frequent awakenings with symptoms. Methods: The study comprised three stages: Stage 1 (2 weeks of no intervention), Stage 2 (8 weeks XD-TOMAC), and Stage 3 (2 weeks of no intervention). XD-TOMAC consisted of bilateral high-frequency peroneal nerve stimulation programmed to 180 min duration and administered nightly at bedtime. Nineteen adults with moderate–severe RLS were enrolled, each reporting at least three nights per week of RLS symptoms causing increased awakenings or interfering with returning to sleep after waking. Results: The intent-to-treat analysis population included all patients who began Stage 2 (n = 15). After 8 weeks of XD-TOMAC, the mean change in International RLS Study Group Rating Scale (IRLS) score was −10.6 points (p < 0.001), and the mean change in Medical Outcomes Study Sleep Problems Index II (MOS-II) was −29.5 points (p < 0.001). The mean change in the number of nocturnal awakenings was −1.1 per night (p = 0.009), and the mean change in sleep efficiency was +8.5% (p = 0.001). The mean change in time awake with RLS symptoms after sleep onset was −28.1 min (p = 0.009). Each of these improvements was sustained at the end of Stage 3 (p < 0.01). There were no serious or severe device-related adverse events. Conclusions: Compared with prior 30 min TOMAC studies, XD-TOMAC demonstrated greater efficacy and similar tolerability, supporting its potential as a nonpharmacological therapy for RLS patients whose symptoms frequently disrupt sleep.

3 June 2026 in SLEEP
Verified
Journal Article
Open access
HSHaramandeep Singh
Haramandeep Singh
MBMark J Buchfuhrer
Mark J Buchfuhrer
JOJoseph Ojile
Joseph Ojile
ARAsim Roy
Asim Roy
RTRobert J. J Thomas
Robert J. J Thomas
JCJonathan D. Charlesworth
Jonathan D. Charlesworth
Study Objectives: The purpose of the THRIVE study is to evaluate the outcomes of patients receiving tonic motor activation (TOMAC) for treatment of refractory restless legs syndrome (RLS) in real-world clinical practice. This article examines outcomes after 90 days of TOMAC treatment. Methods: THRIVE is a multicenter, prospective, observational study that enrolled 325 patients prescribed TOMAC (Nidra) for the treatment of RLS. The indicated intent-to-treat analysis population included adults with refractory moderate–severe RLS. The primary endpoint was change in International RLS Study Group (IRLS) score. Secondary endpoints included Clinician Global Impressions-Improvement score and change in Medical Outcomes Study Sleep Problems Index II (MOS-II) score. Adjunctive RLS medications were assessed at study entry and day 90. Results: A total of 232 patients met criteria for indicated intent-to-treat analysis. Change in IRLS score at day 90 was −8.4 (95% CI: −7.4 to −9.4). Clinician Global Impressions-Improvement responder rate was 64% and mean score was 2.4 (95% CI: 2.2 to 2.6). Change in MOS-II score was −12.8 (95% CI −10.3, −15.3). Reductions to adjunctive RLS medication dosage were more common than increases (19% decreased vs. 11% increased; p = .01) and were well-tolerated (mean IRLS change: −8.1; 95% CI −6.3, −9.9). There were no statistically significant predictors of effectiveness. There were no severe or serious device-related adverse events. Conclusions: In real-world clinical practice, TOMAC is safe and effective at reducing RLS symptoms and improving sleep in adults with moderate-to-severe refractory RLS. Clinical Trial: A Post-Market Study for Long-Term Effectiveness and Safety of the Noctrix TOMAC System for RLS (THRIVE); https://clinicaltrials.gov/study/NCT06076499; Registered at ClinicalTrials.gov with the identifier number NCT06076499 Statement of Significance This paper reports the 90-day results from the first real-world study to evaluate the safety and effectiveness of tonic motor activation (TOMAC) for treatment of refractory restless legs syndrome. We report that the effectiveness and safety of TOMAC is similar in real-world practice compared to controlled trials. This study had the largest sample size and the most heterogeneous patient population of TOMAC clinical trials, thereby allowing comparison of outcomes among different subgroups; we found that TOMAC is equally effective across subgroups. Furthermore, many patients were able to tolerate substantial reduction in dosage of dopamine agonists, which is of great interest given the shift away from dopamine agonists in clinical guidelines due to their risk for augmentation.